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ABSTRACT 
INTRODUCTION Disease occurrence is more in identical twins.Females are 
more prone than male. Female sex hormones may play a 
protective role in RA; for example, the use of the oral 
contraceptive pill and pregnancy are both associated with a 
decreased risk. However, the postpartum period has been 
highlighted as a risk period for the development of RA. (2), 
(3). 
 
Figure 1. Types of Arthritis 
There are two types of arthritic condition for joints. One is 
rheumatoid arthritis and another is osteoarthritis. Diagram 
shows the difference between two types. In osteoarthritis, 
cartilage is getting eroded. Two bone’s ends rub together, 
causes pain and inflammation. In rheumatoid arthritis 
synovial membrane is inflamed. Bone erosion is a central 
feature of rheumatoid arthritis. Bone continuously undergoes 
remodeling by actions of bone resorbing osteoclasts and 
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Rheumatoid arthritis is an autoimmune disorder. It is a chronic progressive 
disease resulting in inflammation of joints and painful deformity and immobility of 
various joints. Being an autoimmune disease, there’s lacuna in proper 
management of the disease. Current options like steroids and DMARD’S (disease 
modifying anti-rheumatic drugs) are the cornerstone in therapy of the disease, 
but have their own limitation. New drugs and better methods for management of 
rheumatoid arthritis are still evolving.  The present review highlights the possible 
involvement of Montelukast, an antagonist of leukotriene receptors and Cetrizine, 
an antihistaminic drug in amelioration of the progression of the disease.   
 
 
Arthritis is a form of joint disorder which involves 
inflammation of one or more joints. There are more than 100 
forms of arthritis are available. Out of them few are common 
like osteoarthritis, rheumatoid arthritis, gout, ankylosing 
spondilytis, and juvenile idiopathic arthritis. Arthritis affects 
the musculoskeletal system, especially the joints. A joint is 
the area in the body where two bones meet and helps in the 
movement of the body parts. It usually causes joint pain. It is 
classified as a rheumatic disease. 
Rheumatoid arthritis is chronic progressive autoimmune 
disorder characterized by symmetric erosive synovitis (1).The 
prevalence of rheumatoid arthritis (RA) is relatively constant 
in many populations, at 0.5–1.0%.The exact etiology behind 
rheumatoid arthritis is unknown till now. There is a genetic 
role in disease risk. Studies have so far shown that the 
familial recurrence risk in RA is small compared with other 
autoimmune diseases. The main genetic risk factor of RA is 
the HLA DRB1 alleles, and this has consistently been shown in 
many populations throughout the world. The strongest 
susceptibility factor so far has been the HLA DRB1*0404 
allele. Tumor necrosis factor alleles have also been linked 
with RA. However, it is estimated that these genes can 
explain only 50% of the genetic effect. A number of other 
non-MHC genes have thus been investigated and linked with 
RAEnvironmental factors have also been studied in relation 
to RA. The geometric distribution of disease is homogenous. 
KEYWORDS: Montelukast, cetrizine, rheumatoid arthritis, leukotriene, histamine.
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bone forming osteoblasts. One of the main triggers of bone 
erosion in the joints in rheumatoid arthritis is inflammation 
of the synovium, caused in part by the production of pro-
inflammatory cytokines and receptor activator of nuclear 
factor kappa B ligand (RANKL), a cell surface protein present 
in Th17 cells and osteoblasts.(4) Osteoclast activity can be 
directly induced by osteoblasts through the RANK/RANKL 
mechanism (5). 
Progression of rheumatoid arthritis: 
The figure 2 shows progression of rheumatoid arthritis. In 
rheumatoid arthritis there are three phases of progression: 
1. Initiation  
2. Inflammation 
3. Destruction 
First stage is initiation of disease. In this stage destructive 
changes are not seen. At this stage innate immunity 
activators get activates. In progression of disease FLS, 
mastocyte, dendriatic cells and macrophages are involved. 
Activators activates chemokines, cytokines, and adhesion 
molecule. Second stage is inflammation; in this joint 
deformities are not seen but limitation of joint mobility may 
be present. Adjacent muscle atrophy, extra-articular soft 
tissue lesions can be seen. Joint destruction gets started. 
Osteoclast has formed. Auto antibodies, prostaglandins, and 
proteases get activated. Third stage is destruction; cartilage 
and bone destruction is seen. Extensive muscle atrophy and 
joint deformities are symptoms. Here panus is formed and 
aggressive FLS formed. 
 
Figure 2. Schematic diagram of disease mechanisms that 
likely occur in various phases of rheumatoid arthritis 
2.1 Treatment approaches: 
Rheumatoid arthritis is an autoimmune disease, so it is not 
just the treatment of disease but it is a management of 
disease. The main objective of treatment is to relief the 
symptoms, restrict the articular damage, stop the 
progression of disease, and improve the quality of life. There 
are 5 main principles 
1. Relief of pain 
2. Reduction of inflammation 
3. Protection of articular structure 
4. Maintenance of  function 
5. Control of systemic involvement(6) 
 
 
 
 
2.2 Current drug treatments. 
A. Disease modifying ant rheumatic drugs (DMARDs)  
1. Immunosuppressant: Methotrexate, Azathioprine, 
Cyclosporine  
2. Sulfasalazine  
3. Chloroquine or Hydroxychloroquine 
4. Leflunomide 
5. Gold sod. Thiomalate, Auranofin 
6. d-Penicillamine 
B. biologic response modifier 
1. TNF – α inhibitor - Etanercept, Infliximab, adalimumab 
2. IL-1 antagonist – anakinara 
C. Adjuvant drugs 
Corticosteroids, prednisolone, and other (7) 
2.3 Treatments and safety issues (8) 
Rheumatoid arthritis is a chronic disease, so patients need to 
take therapy for long time. 
It will increase the risk of side effects of drugs to the patients. 
Some common side effects of traditional drugs are listed 
below. 
Table 1. Treatment approach 
NSAID’s  
 
Indigestion  
gastrointestinal disturbance 
Stomach ulcers  
COX 2 
inhibitors 
Increased risk of cardiovascular events 
aggravation of hypertension 
Corticosteroids Weight gain 
cushingoid appearance 
increased blood pressure, increased 
blood sugar level 
Osteoporosis  
DMARD’S Hepatic cirrhosis 
Interstitial pneumonitis 
Severe myelosuppression 
Cancer risk with methotrexate 
Biologics Systemic lupus erythromatus 
Injection or infusion site reactions  
JAK inhibitors Infection and malignancy  
Gastrointestinal perforation  
 
3. Montelukast: 
3.1 Structure: Montelukast sodium is a selective and 
orally active leukotriene receptor antagonist that inhibits the 
cysteinyl leukotriene CysLT1 receptor. 
Montelukast sodium is described chemically as [R-(E)]-1-[[[1-
[3-[2-(7-chloro-2 quinolinyl) ethenyl] phenyl]-3-[2-(1-hydroxy-
1-methylethyl) phenyl] propyl] thio] methyl] 
cyclopropaneacetic acid, monosodium salt. The empirical 
formula is C35H35ClNNaO3S, and its molecular weight is 
608.18. 
 
 
 
 
Page 35Vikram V Nimbalkar et al.
Int J Clin and Biomed Res. 2016;2(3): 34-38 
 
 The structural formula is: 
H
H
N
Cl
S
O
O
H
O H
 
Figure 3. Structure of Montelukast 
 
3.2 Pharmacology: 
3.2.1 Pharmacodynamics: 
Montelukast is a leukotriene receptor antagonist used as an 
alternative to anti-inflammatory medications in the 
management and chronic treatment of asthma and exercise-
induced bronchospasm (EIB). Unlike zafirlukast, Montelukast 
does not inhibit CYP2C9 or CYP3A4 and is, therefore, not 
expected to affect the hepatic clearance of drugs 
metabolized by these enzymes. 
3.2.2 Pharmacokinetics: The leukotriene-modifying drugs 
are administered orally. Montelukast is absorbed rapidly, 
with ~60–70% bioavailability. At therapeutic 
concentrations,it is highly protein-bound (99%). It is 
metabolized extensively by CYP3A4 and CYP2C9. The t1/2of 
Montelukast is 3–6 hours, with volume of distribution of 8 to 
11 lit.(9) 
3.3 Clinical uses: Montelukast sodium, a cysteinyl 
leukotriene receptor antagonist, is approved for the 
treatment of asthma. Leukotrienes are one of the main 
inflammatory mediators released during the body's reaction 
to allergen exposure. They are produced from arachidonic 
acid via the 5-lipoxygenase pathway and include LTC4, LTD4, 
and LTE4. They are released by many inflammatory cells, 
including eosinophils, mast cells, monocytes, basophils, and 
neutrophils. Montelukast, primarily a cysteinyl leukotriene 
(CysLT1) receptor antagonist, exhibited previously 
undocumented, secondary, neutrophil-directed anti-
inflammatory properties, which appeared to be cAMP-
dependent. (10) (11). 
 
Figure 4. Leukotriene Formation 
3.4 Side effects: Montelukast is very safe with few side 
effects like headache, rashes. Eosinophilia and 
neuropathy are infrequent. 
4 Cetrizine: 
Structure: Cetirizine is a potent second-generation histamine 
H1 antagonist that is effective in the treatment of allergic 
rhinitis, chronic urticaria, and pollen-induced asthma. Unlike 
many traditional antihistamines, it does not cause drowsiness 
or anticholinergic side effects. 
Cetrizine described chemically as2-[2-[4-[(4-chlorophenyl)-
phenylmethyl]piperazin-1-yl]ethoxy]acetic acid. The 
molecular formula is C21H25ClN2O3 with molecular weight 
388.8878 g/mol. 
Cl
N
N
O
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O
 
Figure 5. Structure of Cetrizine 
 
4.1 Pharmacology: 
4.1.1 Pharmacodynamics: Cetirizine is a metabolite 
of hydroxyzine and a selective peripheral histamine H1-
receptor antagonist. It is used for symptomatic treatment of 
seasonal and perennial allergic rhinitis and for chronic 
urticaria. 
4.1.2 Pharmacokinetics:Cetrizine is orally absorbed. Its 
half life is 8.3 hours with clearance rate of 53 mL/min. 
4.2 Clinical uses: Cetrizine is an antihistamine that 
reduces the natural chemical histamine in the body. 
Histamine can produce symptoms of sneezing, itching, 
watery eyes, and runny nose. Cetrizine is the 2nd generation 
H1 receptor blocker. The prevalence of allergic conditions 
and the relative safety of the drugs contribute to heavy use 
of it. 
1. Allergic Reactions 
2. Motion Sickness and Vestibular Disturbances 
3. Nausea and Vomiting of Pregnancy 
4.3 Side effects:Less common toxic effects of systemic 
use include excitation and convulsions in children, postural 
hypotension, and allergic responses. (12) 
4.4 Mechanism of action: Cetirizine competes 
with histamine for binding at H1-receptor sites on the 
effector cell surface, resulting in suppression of histaminic 
edema, flare, and pruritus. The low incidence of sedation can 
be attributed to reduced penetration of cetirizine into the 
CNS as a result of the less lipophilic carboxyl group on 
the ethylamine side chain. 
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Figure 6.  Inflammatory mediators 
Cetirizine, supposed to inhibit DNA binding activity of NF-
kappa B, inhibits the expression of adhesion molecules on 
immunocytes and endothelial cells and the production of IL-8 
and LTB4, two potent chemo attractants, by immune cells. It 
induces the release of PGE2, a suppressor of antigen 
presentation and MHC class II expression, from 
monocyte/macrophages and reduces the number of tryptase 
positive mast cells in inflammation sites. Tryptase is a chemo 
attractant, generates kinins from kininogen, activates mast 
cells, triggers maturation of dendritic cells and stimulates the 
release of IL-8 from endothelial cells and the production of 
Th1 lymphokines by mononuclear immunocytes. (13) 
 
HYPOTHESIS 
As we seen earlier, progression of disease goes through three 
steps; Initiation, inflammation, and destruction. In second 
stage inflammation, interleukins plays important role. 
Montelukast acts as leukotriene receptor antagonist. 
Leukotrienes are produced by many cells of the body and 
mediate many aspects of the inflammatory response. 
Arachidonic acid is converted into leukotriene A4 (LTA4), 
which will further produce leukotriene C4 (LTC4) and 
leukotriene B4 (LTB4). These leukotriene triggers 
inflammatory responses, so that one can restrict the 
progression of disease at second stage only. This will be new 
approach for the treatment of rheumatoid arthritis. 
Cetrizine is very popular anti-histaminic drug. Cetrizine 
restrict the activity of histamine. Cetirizine, supposed to 
inhibit DNA binding activity of NF-kappa B, inhibits the 
expression of adhesion molecules on immunocytes and 
endothelial cells and the production of IL-8 and LTB4, two 
potent chemo attractants, by immune cells. It induces the 
release of PGE2, a suppressor of antigen presentation and 
MHC class II expression, from monocyte/macrophages and 
reduces the number of tryptase positive mast cells in 
inflammation sites. Tryptase is a chemo attractant, generates 
kinins from kininogen, activates mast cells, triggers 
maturation of dendritic cells and stimulates the release of IL-
8 from endothelial cells and the production of Th1 
lymphokines by mononuclear immunocytes. Cetrizine may 
prove benefit in improvement of rheumatoid arthritis. 
 
  
 
CONCLUSION 
Rheumatoid arthritis is an autoimmune disease; there is 
lacuna in proper management of disease. This study puts 
forth a new approach of Montelukast and Cetrizine in 
treatment of rheumatoid arthritis. It also highlights the 
probable mechanism of action involved in treatment of 
disease.  
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